Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.

被引：0
|
作者：
Zhang, Xing
Wen, Xizhi
Chen, Guojuan
Zeng, Shan
Men, Lichuang
Wang, Hengbang
He, Shulan
Ma, Yuxiang
Pan, QiuZhong
Zhang, Yang
Peng, Ruiqing
Weng, Desheng
Liu, Wenqin
Zhang, Li
Liang, Zhiyan
Yang, Dajun
Zhai, Yifan
机构：
[1] Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, Canc Ctr, Guangzhou, Peoples R China
[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[4] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11542
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
    Patnaik, Amita
    Tolcher, Anthony
    Beeram, Muralidhar
    Nemunaitis, John
    Weiss, Glen
    Nichols, Gwen
    Middleton, Steven
    Sarapa, Nenad
    Beryozkina, Anna
    Zhi, Jianguo
    CANCER RESEARCH, 2013, 73 (08)
  • [42] A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.
    Rasco, Drew W.
    Li, Yufeng
    Tang, Yuefen
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Liang, Zhiyan
    Sun, Joan
    Amaya, Alex
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
    Tolcher, Anthony W.
    Reeves, James Andrew
    McKean, Meredith
    Chmielowski, Bartosz
    Beck, Joseph Thaddeus
    Shaheen, Montaser F.
    Somaiah, Neeta
    Wilson, Melissa
    Spira, Alexander I.
    Drabick, Joseph J.
    Tang, Yuefen
    Winkler, Robert
    Li, Mingyu
    Ahmad, Mohammad
    Lu, Ming
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2-p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study
    Peltzer, Alexander
    LoRusso, Patricia
    Gounder, Mrinal M.
    Yamamoto, Noboru
    Somaiah, Neeta
    Lugowska, Iwona A.
    Moreno, Victor
    Teufel, Michael
    Jayadeva, Girish
    Hesse, Raphael
    Sturm, Gregor
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma
    Langenberg, M. H.
    Gluck, L.
    Weger, V.
    Frank, R.
    Eskens, F.
    Blay, J. Y.
    Soria, J. C.
    Chawla, S.
    Gounder, M.
    Wagner, A.
    Zhang, Y.
    Kambuj, P.
    Loberg, R.
    Henary, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S34 - S34
  • [46] Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
    Schoffski, Patrick
    Lahmar, Mehdi
    Lucarelli, Anthony
    Maki, Robert G.
    FUTURE ONCOLOGY, 2022, 19 (09) : 621 - 629
  • [47] A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors
    Zhang, X.
    Wen, X.
    Peng, R.
    Pan, Q.
    Weng, D.
    Ma, Y.
    Zhang, Y.
    Yang, J.
    Men, L.
    Wang, H.
    Liang, E.
    Wang, C.
    Yang, D.
    Zhang, L.
    Zhai, Y.
    ESMO OPEN, 2024, 9 (08)
  • [48] Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors.
    Liu, Chang
    Zhang, Miao
    Yuan, Jiajia
    Liu, Dan
    Gong, Jifang
    Zhu, Yi
    Lin, Lishan
    Sun, Yongkui
    Nippgen, Johannes
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors.
    Zafar, Y.
    Bendell, J.
    Lager, J.
    Yu, D.
    George, D.
    Nixon, A.
    Petros, W.
    Beci, R.
    Arrowood, C.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 145S - 145S
  • [50] Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.
    Swiecicki, Paul
    Tang, Yuefen
    Pearson, Alexander T.
    Muzaffar, Jameel
    Fidler, Mary J.
    Winkler, Robert
    Fu, Tommy
    Li, Mingyu
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345